Fanny Piette - Concepedia

Author

Fanny Piette

International Drug Development Institute (Belgium)

Also Known As

F Piette, F. Piette, Fanny Piette

Publications

Citations

H-Index

Concepts

All Affiliations

International Drug Development Institute (Belgium)Institut Jules Bordet Hôpital Claude Huriez UPMC Hillman Cancer Center NSABP Foundation

About

Fanny Piette is an author at International Drug Development Institute (Belgium) specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	285
2	Public Health	1	1	12
3	Allergy	1	1	89
4	Biostatistics	1	1	12
5	Blood Transplantation	1	1	57

Fanny Piette

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 Sherene Loi, Nicolas Sirtaine, Fanny Piette, Journal of Clinical Oncology	2013	1.6K
Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer Marc Buyse, Sherene Loi, Laura van’t Veer, JNCI Journal of the National Cancer Institute	2006	1.2K
Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series Christine Desmedt, Fanny Piette, Sherene Loi, Clinical Cancer Research	2007	968
Destructive Cleavage of Antigenic Peptides Either by the Immunoproteasome or by the Standard Proteasome Results in Differential Antigen Presentation Jacques Chapiro, Stéphane Claverol, Fanny Piette, The Journal of Immunology	2006	157
Comparison of prognostic gene expression signatures for breast cancer Benjamin Haibe‐Kains, Christine Desmedt, Fanny Piette, BMC Genomics	2008	139
Blau syndrome of granulomatous arthritis, iritis, and skin rash: A new family and review of the literature Sylvie Manouvrier‐Hanu, Bernard Puech, Fanny Piette, American Journal of Medical Genetics Ocular DiseaseVasculitisSkin RashDermatologyEye Involvement	1998	89
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10 Jame Abraham, A.J. Montero, Rachel C. Jankowitz, Journal of Clinical Oncology	2019	79
A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. Angelo Di Leo, J Isola, Fanny Piette, Cancer Research Breast OncologyPathologyPredictive ValueTumor BiologyColor Fish Test	2009	57
Unrelated Donor Status and High Donor Age Independently Affect Immunologic Recovery after Nonmyeloablative Conditioning Frédéric Baron, Barry E. Storer, Michael B. Maris, Biology of Blood and Marrow Transplantation Transplant RejectionCell TherapyTransplantationAutoimmune DiseaseT Cells	2006	57
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types Caroline Lonez, Bikash Verma, Alain Hendlisz, BMJ Open	2017	48

Page 1